New Product Launch Aytu BioPharma recently launched EXXUA, the first extended-release tablets of gepirone indicated for major depressive disorder, providing an opportunity to target mental health market segments and mental health care providers.

Market Expansion With the commercial availability of EXXUA across the U.S. and active participation in investor conferences, the company is positioned for increased outreach to healthcare providers and payers, opening avenues for expanded sales channels.

Strategic Collaborations Partnerships with firms like Fabre-Kramer Pharmaceuticals support commercialization efforts, indicating potential for co-marketing and distribution opportunities within the CNS treatment domain.

Growth Focus The company's recent product launch and investor engagements highlight a growth-oriented approach, suggesting opportunities to cater to clinics, hospitals, and mental health specialty centers seeking innovative CNS therapies.

Targeted Market Given its focus on complex CNS diseases and recent product introduction, sales strategies should target neuropsychiatry specialists, mental health clinics, and healthcare institutions prioritizing advanced depression treatments.